Global Synthetic Lethality-based Drugs and Targets Market Size By Type (Monotherapy, Combination Therapy), By Application (Medical Research Institution, Hospital and Clinic), By Region, And Segment Fo...

The Global Synthetic Lethality-based Drugs and Targets Market was valued at USD 1.2 billion in 2023 and is projected to surpass USD 5.7 billion by 2031, expanding at a CAGR of 21.9% during the forecast period from 2023 to 2031. The growing focus on precision oncology, along with significant advances in genetic screening and biomarker discovery, is driving the demand for synthetic lethality-based therapies. These treatments target the genetic vulnerabilities of cancer cells while sparing normal cells, offering a promising alternative to traditional chemotherapy.

The market is gaining momentum as research institutions and biopharma companies increasingly invest in developing targeted therapies that exploit synthetic lethal interactions, particularly for hard-to-treat cancers such as triple-negative breast cancer and ovarian cancer.

Drivers:

1. Increasing Demand for Targeted Cancer Therapies:

Synthetic lethality-based treatments are revolutionizing oncology by enabling highly selective targeting of cancer cells. This approach reduces systemic toxicity and enhances therapeutic efficacy, especially in tumors with BRCA1/2 and other DNA repair deficiencies.

2. Advances in Genomic Technologies:

The rise of CRISPR-Cas9, next-generation sequencing (NGS), and functional genomics platforms is facilitating the identification of novel synthetic lethal gene pairs. These advancements are rapidly expanding the druggable landscape.

3. Growth in Personalized Medicine:

The global shift towards personalized cancer therapy is propelling the development of synthetic lethality drugs, which are tailored based on patients’ unique genetic profiles.

Restraints:

1. Complexity of Drug Development:

Developing synthetic lethality-based drugs requires complex preclinical validation and biomarker discovery, increasing R&D costs and timelines.

2. Limited Clinical Validation:

Although promising in preclinical studies, only a few synthetic lethality targets (e.g., PARP inhibitors) have been successfully translated into approved drugs. Broader clinical validation is still underway.

Opportunity:

1. Expansion into Solid Tumor Indications:

Ongoing trials are exploring synthetic lethality for a wide range of solid tumors, presenting significant growth opportunities beyond current niche indications.

2. Strategic Collaborations and Licensing Deals:

Biotech firms are increasingly entering partnerships with pharmaceutical giants and academic institutions to co-develop synthetic lethality platforms, accelerating drug discovery and commercialization efforts.

Market by System Type Insights:

Small Molecule Inhibitors dominate the system type segment, accounting for the largest market share in 2023. These agents have demonstrated robust preclinical and clinical activity, particularly in inhibiting PARP enzymes. Meanwhile, Gene Silencing and Editing Tools such as siRNA and CRISPR are gaining traction for their potential in exploring novel synthetic lethal targets and enhancing therapeutic precision.

Market by End-use Insights:

Biopharmaceutical Companies emerged as the largest end-user segment in 2023. These companies lead in developing synthetic lethality-based drug candidates, often in collaboration with academic research centers. Academic & Research Institutes are also pivotal in early-stage discovery, driving innovation through grant-supported projects and translational research.

Market by Regional Insights:

North America led the global market in 2023, supported by strong R&D funding, early adoption of novel oncology therapies, and a high prevalence of cancer. The Asia-Pacific region is anticipated to exhibit the fastest growth, driven by expanding clinical trial activities, increasing healthcare investments, and growing awareness about personalized cancer treatments in countries like China, Japan, and South Korea.

Competitive Scenario:

Key players in the Global Synthetic Lethality-based Drugs and Targets Market include:

AstraZeneca PLC

Bayer AG

Repare Therapeutics

IDEAYA Biosciences

Cyteir Therapeutics

Artios Pharma

CRISPR Therapeutics

Tango Therapeutics

These companies are focusing on clinical pipeline expansion, licensing agreements, and the identification of novel gene interactions. For instance:

In 2024, IDEAYA Biosciences advanced its MAT2A inhibitor into Phase 2 trials for solid tumors with MTAP deletion.

Repare Therapeutics signed a collaboration deal with Roche in 2023 for the development of synthetic lethality therapeutics, valued at over USD 1.2 billion.

Artios Pharma received orphan drug designation in 2023 for its DNA polymerase theta inhibitor targeting homologous recombination-deficient tumors.

Scope of Work – Global Synthetic Lethality-based Drugs and Targets Market

Report Metric Details

Market Size (2023) USD 1.2 billion

Projected Market Size (2031) USD 5.7 billion

CAGR (2023–2031) 21.9%

Market Segments System Type (Small Molecule Inhibitors, Gene Editing Tools), End-use (Biopharmaceutical Companies, Academic Institutes), Region

Growth Drivers Rising demand for precision oncology, genomic tech advancements

Opportunities Expansion to new tumor types, R&D collaborations

Key Market Developments:

January 2023: AstraZeneca expanded its synthetic lethality portfolio with the launch of a new clinical trial targeting DDR-deficient breast cancer.

June 2023: CRISPR Therapeutics collaborated with Vertex Pharmaceuticals to identify novel synthetic lethal targets using CRISPR-Cas9 screening.

February 2024: Tango Therapeutics reported promising Phase 1 data on its PRMT5 inhibitor for MTAP-deleted tumors.

FAQs

1. What is the current market size of the Global Synthetic Lethality-based Drugs and Targets Market?

The market was valued at USD 1.2 billion in 2023.

2. What is the major growth driver of the Global Synthetic Lethality-based Drugs and Targets Market?

The increasing demand for personalized cancer treatments and advancements in genomic technologies are the major growth drivers.

3. Which is the largest region during the forecast period in the Global Synthetic Lethality-based Drugs and Targets Market?

North America is projected to remain the largest region during the forecast period.

4. Which segment accounted for the largest market share in the Global Synthetic Lethality-based Drugs and Targets Market?

The Small Molecule Inhibitors segment accounted for the largest share in 2023.

5. Who are the key market players in the Global Synthetic Lethality-based Drugs and Targets Market?

Key players include AstraZeneca, Repare Therapeutics, IDEAYA Biosciences, Tango Therapeutics, Artios Pharma, and Bayer AG.